A day split between biotech momentum and infrastructure capital deployment. The weight fell on companies with binary catalysts—trial outcomes and expansion commitments—that moved large-cap equities on fundamental news rather than macro shifts.

• Moderna's cancer vaccine clears Phase 3 trial against standard treatment
• Micron commits to major Boise expansion, strains regional housing and traffic

Sources: Cointelegraph, CoinDesk, CNBC, Decrypt, The Block, MarketWatch, The Defiant

This article is for information only and is not financial advice.